[The effect of D-penicillamine on the galactosamine hepatitis model in the rat].
D000284:Administration, Oral; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology / Q000517:prevention & control*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005688:Galactosamine; D008055:Lipids / Q000097:blood; D008099:Liver / Q000201:enzymology / Q000378:metabolism; D010396:Penicillamine / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D014500:Uracil Nucleotides / Q000378:metabolism
D008055:Lipids; D014500:Uracil Nucleotides; D005688:Galactosamine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D010396:Penicillamine
Die Wirkung von D-Penicillamin am Galactosamin-Hepatitis-Modell der Ratte.